官方服务：
资源简介：
Antitumor drug therapy of lung cancer
应用场景：
创建时间：
2024-06-04
相关数据集
Pulmonary Drugs Market Size, Trends and Forecast to 2030
Pulmonary Drugs Market to be valued at $77.31 Bn by 2030. Report: Industry Size, Y-o-Y Growth Rate, Epidemiology, Prevalence Rate
www.coherentmarketinsights.com120
Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)
PURPOSE: This randomized phase III trial is studying maintenance therapy with bevacizumab alone after an induction therapy combining bevacizumab+chemotherapy to see how well they work compared to main
NIAID Data Ecosystem40
Tumor number and volume of offspring at sacrifice (22 weeks).
Data expressed as Mean��SEM and differences between treatment groups were determined by one way ANOVA and appropriate post hoc test. Differences with a p*. n = number of mice/group, tumor volume expre
Figshare2015-12-02 更新10
XELOX(+bevacizumab), efficacy, safety, QOL Study:FOLFOX(+bevacizumab) after starting therapy, for patients can’t continue continuous infusion therapy
Interventions: 1000mg/m2 of oral Xeloda twice daily on days 1 through 14 every 3 weeks. L-OHP 130mg/m2 is administered intravenous injection on day 1. (Bevacizumab 7.5mg/kg is administered intravenous
NIAID Data Ecosystem40
